|
|
|
|
|
Mechlorethamine
drug data and news
Mechlorethamine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Mechlorethamine | ||
| Brand Names/Synonyms | Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Dichlor Amine; Dichloren; Embichin; HN2; MBA; Mechlorethamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mustine Note; Mutagen; NSC 762; Nitrogen Mustard; T-1024; TL 146 | ||
| Indication | For the palliative treatment of Hodgkin’s disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Mechlorethamine is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. | ||
| Mechanism Of Action | Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. | ||
| Mechlorethamine News (When available) |
ACS News Center, At least one laboratory study suggests curcumin may inhibit the action of other chemotherapy drugs, including camptothecin, mechlorethamine, doxorubicin, and ... | ||
| Dosage Forms | Powdered vials for injection, skin solution and ointment | ||
| Drug_Category | Antineoplastic Agents; Chemical Warfare Agents; Alkylating Agents; ATC:L01A | ||
| Absorption | Mechlorethamine is incompletely absorbed following intracavitary administration, probably because of rapid deactivation by body fluids. | ||
| Interactions |
Interactions for Mechlorethamine: No information provided. | ||
| Toxicity | Very toxic. May lead to severe leukopenia, anemia, thrombocytopenia and a hemorrhagic diathesis with subsequent delayed bleeding may develop. Death may follow, LD50=1.6 mg/kg (orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-chloro-N-(2-chloroethyl)-N-methyl-ethanamine | ||
| Chemical Formula | C5H11Cl2N | ||
| Molecular Weight | 156.053 g/mol | ||
| Smiles String | CN(CCCl)CCCl | ||
| Melting Point | 109-111 °C | ||
| Water Solubility | 120 mg/mL | ||
| State | Solid; hydroscopic powder | ||
| LogP/Hphobicity | 1.412 | ||
| Isoelectric Point | 6.76 | ||
| Biotransformation | Systemic - Rapidly deactivated in body fluids and tissues. | ||
| Half Life | 15 minutes | ||
| Protein Binding [%] | Not available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00249 | ||
| CAS Registry Number | 51-75-2 | ||
| KEGG Compound ID | C07115 | ||
| PubChem ID | SID:307834 | ||
| PharmGKB ID | PA450336 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 16063 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |